Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 4/20 | 0.49 |
| ▸ | CYP11B2 | P19099 | 4/20 | 0.49 |
| ▸ | SLC22A12 | Q96S37 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.38 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.38 |
| ▸ | SLC22A11 | Q9NSA0 | 1/20 | 0.38 |
| ▸ | PRKAB2 | O43741 | 1/20 | 0.38 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.38 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.38 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 0.38 |
| ▸ | PRKAG3 | Q9UGI9 | 1/20 | 0.38 |
| ▸ | PRKAG2 | Q9UGJ0 | 1/20 | 0.38 |
| ▸ | PRKAB1 | Q9Y478 | 1/20 | 0.38 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.36 |
| ▸ | DAO | P14920 | 1/20 | 0.36 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29920114 | 1.00 | CYP11B1 (0.49) | CYP11B1CYP11B2SLC22A12POLBHCAR2 | |
| SCHEMBL29207918 | 0.84 | KDM4E (0.40) | CYP11B1CYP11B2SLC22A12POLBHCAR2 | |
| SCHEMBL24534060 | 0.82 | CYP11B1 (0.42) | CYP11B1CYP11B2SLC22A12POLBHCAR2 | |
| SCHEMBL3507833 | 0.82 | CYP11B1 (0.42) | CYP11B1CYP11B2SLC22A12POLBHCAR2 | |
| SCHEMBL3749196 | 0.82 | CYP11B1 (0.43) | CYP11B1CYP11B2SLC22A12CYP3A4CYP2C9 | |
| SCHEMBL30964464 | 0.79 | CYP11B1 (0.40) | CYP11B1CYP11B2SLC22A12POLBHCAR2 | |
| SCHEMBL15463724 | 0.79 | NR1H2 (0.40) | CYP11B1CYP11B2SLC22A12POLBHCAR2 | |
| SCHEMBL24533960 | 0.77 | CYP11B1 (0.39) | CYP11B1CYP11B2SLC22A12POLBHCAR2 | |
| SCHEMBL2732538 | 0.76 | CYP1A2 (0.39) | CYP11B1CYP11B2SLC22A12POLBHCAR2 | |
| SCHEMBL5160 | 0.76 | CYP11B1 (0.61) | CYP11B1CYP11B2S1PR1PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 723 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4747247-A1 | NOVEL FATTY ACID AMIDE HYDROLASE MODULATORS, COMPOSITIONS COMPRISING THE SAME AND USES THEREOF | Apogee Pharmaceuticals, Inc. (CA) | 2026-05-27 | — | — | EP | disclosed |
| CN-122079983-A | FGFR3 inhibitor compounds | — | 2026-05-26 | — | — | CN | disclosed |
| CN-122079985-A | FGFR3 inhibitor compounds | — | 2026-05-26 | — | — | CN | disclosed |
| CN-122079984-A | FGFR3 inhibitor compounds | — | 2026-05-26 | — | — | CN | disclosed |
| CN-117659017-B | TRPML1/2 modulator compound, pharmaceutical composition, preparation method and application thereof | 北京华益健康药物研究中心 | 2026-05-15 | — | — | CN | disclosed |
| EP-4073062-B1 | FUNCTIONALIZED HETEROCYCLIC COMPOUNDS AS MODULATORS OF STIMULATOR OF INTERFERON GENES (STING) | RYVU THERAPEUTICS S A (PL) | 2026-04-29 | — | — | EP | disclosed |
| US-12612380-B2 | Non-lysosomal glucosylceramidase inhibitors and uses thereof | ALECTOS THERAPEUTICS 1NC (CA) | 2026-04-28 | — | — | US | disclosed |
| EP-3710428-B1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | CALICO LIFE SCIENCES LLC (US) | 2026-03-25 | — | — | EP | disclosed |
| US-12583815-B2 | Inhibitors of YAP/TAZ-TEAD oncoproteins, synthesis and use thereof | BRIDGENE BIOSCIENCES, INC. (US) | 2026-03-24 | — | — | US | disclosed |
| EP-3966199-B1 | NON-LYSOSOMAL GLUCOSYLCERAMIDASE INHIBITORS AND USES THEREOF | ALECTOS THERAPEUTICS INC (CA) | 2026-03-18 | — | — | EP | disclosed |
| EP-1270582-B1 | TRIPHENYLPHOSPHINE DERIVATIVES, PALLADIUM OR NICKEL COMPLEXES THEREOF, AND PROCESS FOR PREPARING BIARYL DERIVATIVES | MITSUBISHI RAYON CO (JP) | 2006-08-30 | — | — | EP | disclosed |
| US-20060160857-A1 | Thiazole-4-carboxyamide derivatives | HOFFMANN-LA ROCHE INC. | 2006-07-20 | — | — | US | disclosed |
| WO-2006074884-A1 | THIAZOLE-4-CARBOXAMIDE DERIVATIVES AS MGLUR5 ANTAGONISTS | F.HOFFMANN-LA ROCHE AG (CH) | 2006-07-20 | — | — | WO | disclosed |
| US-20060020133-A1 | 3-aminocyclopentanecarboxamides as modulators of chemokine receptors | INCYTE CORPORATION | 2006-01-26 | — | — | US | disclosed |
| WO-2006004741-A2 | 3-AMINOCYCLOPENTANECARBOXAMIDES AS MODULATORS OF CHEMOKINE RECEPTORS | INCYTE CORPORATION (US) | 2006-01-12 | — | — | WO | disclosed |
| WO-2006004684-A2 | 3-AMINOCYCLOPENTANECARBOXAMIDES AS MODULATORS OF CHEMOKINE RECEPTORS | INCYTE CORPORATION (US) | 2006-01-12 | — | — | WO | disclosed |
| US-20060004018-A1 | 3-Aminocyclopentanecarboxamides as modulators of chemokine receptors | INCYTE CORPORATION | 2006-01-05 | — | — | US | disclosed |
| US-6693210-B2 | USING PALLADIUM, NICKEL PHOSPHINE COMPLEX AS CATALYSTS | MITSUBISHI RAYON CO., LTD. (JP) | 2004-02-17 | — | — | US | disclosed |
| US-20030065208-A1 | Using palladium, nickel phosphine complex as catalysts | MITSUBISHI RAYON CO., LTD. (JP) | 2003-04-03 | — | — | US | disclosed |
| EP-1270582-A1 | TRIPHENYLPHOSPHINE DERIVATIVE, PRODUCTION PROCESS THEREFOR, PALLADIUM COMPLEX THEREOF, AND PROCESS FOR PRODUCING BIARYL DERIVATIVE | Mitsubishi Rayon Co., Ltd. (JP) | 2003-01-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12583815-B2 | Inhibitors of YAP/TAZ-TEAD oncoproteins, synthesis and use thereof | YAP1, TEAD1, TEAD2 | CYP11B1 3753/4885CYP11B2 4093/4885SLC22A12 2603/4885 |
| US-20060160857-A1 | Thiazole-4-carboxyamide derivatives | GRM1, GRM2, GRIA4 | CYP11B1 2677/4885CYP11B2 2665/4885SLC22A12 982/4885 |
| US-20030065208-A1 | Using palladium, nickel phosphine complex as catalysts | PDCD1LG2, PIK3CA, PDCD1 | CYP11B1 1690/4885CYP11B2 1264/4885SLC22A12 4178/4885 |
| US-20060020133-A1 | 3-aminocyclopentanecarboxamides as modulators of chemokine receptors | CCR5, ACKR3, CXCR3 | CYP11B1 858/4885CYP11B2 901/4885SLC22A12 618/4885 |
| US-20060004018-A1 | 3-Aminocyclopentanecarboxamides as modulators of chemokine receptors | CCR5, ACKR3, CXCR3 | CYP11B1 858/4885CYP11B2 901/4885SLC22A12 618/4885 |
| US-12612380-B2 | Non-lysosomal glucosylceramidase inhibitors and uses thereof | GBA1, GBA2, MAN2B1 | CYP11B1 4261/4885CYP11B2 4349/4885SLC22A12 1285/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.